Atu 027

Drug Profile

Atu 027

Alternative Names: Atu027

Latest Information Update: 17 Oct 2016

Price : $50

At a glance

  • Originator Atugen AG
  • Developer Silence Therapeutics; Silence Therapeutics AG
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action Protein kinase N3 inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I Solid tumours
  • Preclinical Head and neck cancer

Most Recent Events

  • 05 Jan 2016 Silence Therapeutics completes a phase I/II trial in Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease) in Germany (EudraCT2012-004429-26)
  • 10 Jan 2015 Silence Therapeutics withdraws a phase Ib trial in Head and neck cancer in the UK (EudraCT2013-004701-83)
  • 15 Sep 2014 Silence Therapeutics plans a phase Ib trial for Head and neck cancer in the UK (UKCTR16939, EudraCT2013-004701-83)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top